Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Filings indexed 704 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Please see annexed enclosure.
Regulatory Filings Classification · 91% confidence The document is an intimation pursuant to SEBI Listing Regulations disclosing the schedule of analyst and investor meetings. It is a regulatory disclosure to stock exchanges rather than a financial report, management discussion, or presentation itself. It does not contain financial data, vote results, or a report, but serves as a continuous disclosure announcement. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a compliance notification under SEBI LODR Regulation 30 informing stock exchanges of upcoming analyst/institutional investor meetings. It does not contain financial statements, dividend info, capital changes, or the full investor presentation itself—rather it is a general regulatory announcement. No specific filing category (e.g., earnings release, IR, IP) fits this scheduling notice, so it belongs in the fallback category for miscellaneous regulatory disclosures.
2026-05-21 English
Please see annexed enclosure.
Regulatory Filings Classification · 82% confidence The document is a brief notification to stock exchanges announcing inclusion in the Dow Jones Best-in-Class ESG index. It does not contain substantive financial data, a report, or dividend details, nor is it an AGM/EGM voting result or management change. It’s a general regulatory announcement, fitting the fallback category Regulatory Filings (RNS).
2026-05-21 English
Updates
Regulatory Filings Classification · 90% confidence The document is a notification to the BSE and NSE stock exchanges announcing Laurus Labs’ inclusion in the Dow Jones Best-in-Class (DJ BIC) ESG index. It contains no financial statements or management changes; it simply informs regulators/exchanges of a corporate development. This is a typical miscellaneous regulatory announcement, falling under the fallback “Regulatory Filings” category.
2026-05-21 English
Copy of Newspaper Publication
Regulatory Filings Classification · 85% confidence The document is a brief formal disclosure under SEBI Listing Regulations attaching newspaper advertisements regarding the transfer of unclaimed dividends and related shares to the Investor Education and Protection Fund Authority. It does not present financial results, dividend amounts, board changes, or a full financial report, but is a routine compliance announcement to the stock exchanges. This fits under general regulatory filings (fallback category RNS).
2026-05-13 English
Please see annexed enclosure.
Regulatory Filings Classification · 90% confidence The document is a short regulatory disclosure under SEBI LODR Regulation 30 providing copies of newspaper advertisements for a notice to shareholders about transfer of shares to the Investor Education and Protection Fund Authority. It does not contain financial statements or detailed analyst presentation; rather, it is a compliance announcement. This falls under the general regulatory filings category.
2026-05-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.